An Analysis of Photo-CORM Di-(2-hydroxynaphtyl)cyclopropenone

Carbon monoxide (CO) in the last two decades has garnered an increase in interest for its therapeutic effects when applied at a controlled dosage. Some notable effects include antiinflammation, anti-apoptosis, and anti-oxidation. Recently, the use of a molecular vehicle to deliver CO, known as a CO-releasing molecules (CORMs), has been a widely studied topic for their ability to deliver a controlled dosage of CO.

Presented here is the molecule which is a CORM developed in our lab which releases CO through photolysis, thus classifying this compound as a Photo-CORM. Exposure to light, ideally between the wavelengths of 300 – 420 nm, targets the photochemically unstable cyclopropenone ring which induces the release of CO. The characterization and quantification of DHNCP will be discussed alongside the application and future of the project.

References:

1. Motterlini, R.; Clark, J. E.; Foresti, R.; Sarathchandra, P.; Mann, B. E.; Green, C. J. Carbon Monoxide-Releasing Molecules. Circulation Research 2002, 90 (2).
2. Clark, J. E.; Naughton, P.; Shurey, S.; Green, C. J.; Johnson, T. R.; Mann, B. E.; Foresti, R.; Motterlini, R. Cardioprotective Actions by a Water-Soluble Carbon Monoxide– Releasing Molecule. Circulation Research 2003, 93 (2).
3. Yang, X.; Lu, W.; Wang, M.; Tan, C.; Wang, B. “Co in a Pill”: Towards Oral Delivery of Carbon Monoxide for Therapeutic Applications. Journal of Controlled Release 2021, 338, 593–609.
4. Ji, X.; Damera, K.; Zheng, Y.; Yu, B.; Otterbein, L. E.; Wang, B. Toward Carbon Monoxide–Based Therapeutics: Critical Drug Delivery and Developability Issues. Journal of Pharmaceutical Sciences 2016, 105 (2), 406–416.